FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number	3235-0

OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or Sec	tion 30(h)	of the	Investment (Company Ac	t of 1940							
1. Name and Address of Reporting Person* HUMPHREY RACHEL				2. Issuer Name and Ticker or Trading Symbol <u>CytomX Therapeutics</u> , <u>Inc.</u> [CTMX]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) 343 OYSTER POINT BLVD. SUITE 100					3. Date of Earliest Transaction (Month/Day/Year) 01/25/2017						2	X Officer (give title Other (specify below) Chief Medical Officer					
(Street) SOUTH FRANCI	()	A	94080		4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)														
		Та	ble I - Non	-Deriva	tive S	ecuritie	s Ac	cquired, D	isposed (of, or Be	neficially	/ Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution D		Date	Code (Ins			ed (A) or str. 3, 4 and !	Beneficia Owned F	s Illy ollowing	Form (D) or	Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code V	Amount	(A) (D)	Price	Transacti	Reported Transaction(s) (Instr. 3 and 4)			Instr. 4)		
			Table II - D					uired, Dis s, options				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,		saction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	le V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Stock Option (right to buy)	\$11.94	01/25/2017		A		120,000		(1)	01/24/2027	Common Stock	120,000	\$0.00	120,0	00	D		

Explanation of Responses:

1. 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

/s/ Cynthia J. Ladd, as

Attorney-in-Fact for Rachel

01/27/2017

<u>Humphrey</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.